Top

BMC Gastroenterology

Published in:

Open Access 01-12-2024 | Lubiprostone | Research

Comparative profiles of lubiprostone, linaclotide, and elobixibat for chronic constipation: a systematic literature review with meta-analysis and number needed to treat/harm

Authors: Satish S. Rao, Noriaki Manabe, Yusuke Karasawa, Yuko Hasebe, Kazutaka Nozawa, Atsushi Nakajima, Shin Fukudo

Published in: BMC Gastroenterology | Issue 1/2024

Abstract

Objective

To comprehensively evaluate the efficacy, safety, patient symptoms, and quality-of-life (QoL) of lubiprostone, linaclotide, and elobixibat as treatment for chronic constipation (CC).

Design

Systematic literature review (SLR) and meta-analysis (MA). Literature searches were conducted on PubMed and Embase using the Ovid platform.

Methods

SLR including randomized controlled trials (RCTs) and observational studies was conducted to identify the overall efficacy and safety of lubiprostone, linaclotide, and elobixibat. Thereafter, MA was performed using only RCTs. The number needed to treat (NNT) and number needed to harm (NNH) analyses were additionally conducted.

Primary and secondary outcome measures

The primary outcome was efficacy regarding change in spontaneous bowel movements. Secondary outcomes included safety, constipation-related symptoms, and QoL.

Results

Twenty-four studies met the inclusion criteria for the SLR: 17 RCTs, 4 observational studies, and 3 single-arm trials. Feasibility assessment for the MA resulted in 14 studies available for safety data analysis, and 8 available for efficacy analysis, respectively. Three drugs showed similar efficacy in the MA and NNT analysis. However, the NNH analysis revealed distinct safety profiles: lubiprostone, linaclotide, and elobixibat were linked to the highest risk of nausea, diarrhea, and abdominal pain, respectively.

Conclusion

The current study provides an updated overview of the efficacy, safety, patient symptoms, and QoL of the three drugs with different mechanisms of action for CC treatment.The findings could help physicians adopt an individualized approach for treating patients with CC in clinical practice.

Available only for authorised users

Lindberg G, Hamid SS, Malfertheiner P, Thomsen OO, Fernandez LB, Garisch J, et al. 1. World Gastroenterology Organisation global guideline: Constipation–a global perspective. J Clin Gastroenterol. 2011;45(6):483–7. https://doi.org/10.1097/MCG.0b013e31820fb914. PubMed PMID: 21666546.CrossRefPubMed

Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M et al. 2. Bowel Disorders. Gastroenterology. 2016. Epub 20160218. https://doi.org/10.1053/j.gastro.2016.02.031. PubMed PMID: 27144627.

Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. 3. Worldwide Prevalence and Burden of Functional Gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99–114e3. https://doi.org/10.1053/j.gastro.2020.04.014. PubMed PMID: 32294476.CrossRefPubMed

Peppas G, Alexiou VG, Mourtzoukou E, Falagas ME. 4. Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol. 2008;8:5. https://doi.org/10.1186/1471-230x-8-5. PubMed PMID: 18269746; PubMed Central PMCID: PMCPMC2258300.CrossRefPubMedPubMedCentral

Lacy BE. 5. Update on the management of chronic idiopathic constipation. Am J Manag Care. 2019;25(4 Suppl):S55-s62. PubMed PMID: 31002489.

Otani K, Watanabe T, Takahashi K, Nadatani Y, Fukunaga S, Hosomi S, et al. 6. Prevalence and risk factors of functional constipation in the Rome IV criteria during a medical check-up in Japan. J Gastroenterol Hepatol. 2021;36(8):2157–64. https://doi.org/10.1111/jgh.15436. PubMed PMID: 33555082.CrossRefPubMed

Vazquez Roque M, Bouras EP. 7. Epidemiology and management of chronic constipation in elderly patients. Clin Interv Aging. 2015;10:919 – 30. Epub 20150602. doi: 10.2147/cia.S54304. PubMed PMID: 26082622; PubMed Central PMCID: PMCPMC4459612.

Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K. 8. The health-related quality of life and economic burden of constipation. Pharmacoeconomics. 2005;23(5):461 – 76. https://doi.org/10.2165/00019053-200523050-00006. PubMed PMID: 15896098.

Chang L, Chey WD, Imdad A, Almario CV, Bharucha AE, Diem S, et al. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. Am J Gastroenterol. 2023;118(6):936–54. https://doi.org/10.14309/ajg.0000000000002227. PubMed PMID: 37204227; PubMed Central PMCID: PMCPMC10544839.CrossRefPubMed

10.

Vriesman MH, Koppen IJN, Camilleri M, Di Lorenzo C, Benninga MA. Management of functional constipation in children and adults. Nat Rev Gastroenterol Hepatol. 2020;17(1):21–39. https://doi.org/10.1038/s41575-019-0222-y. Epub 20191105. PubMed PMID: 31690829.CrossRefPubMed

11.

Johanson JF, Kralstein J. 11. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25(5):599–608. https://doi.org/10.1111/j.1365-2036.2006.03238.x. PubMed PMID: 17305761.

12.

Hayashi T, Miwa H. Treatment satisfaction with current medications for chronic constipation: an internet survey of Japanese patients. J Clin Gastroenterol. 2022;56(1):e64–e70. https://doi.org/10.1097/mcg.0000000000001473. PubMed PMID: 33337642; PubMed Central PMCID: PMCPMC8647691.CrossRefPubMed

13.

Johanson JF, Ueno R. 23. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25(11):1351-61. https://doi.org/10.1111/j.1365-2036.2007.03320.x. PubMed PMID: 17509103.

14.

Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, et al. 47. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 2010;86(19–20):760–5. PubMed PMID: 20307554.CrossRefPubMed

15.

Miner PB. Jr. 12. Elobixibat, the first-in-class Ileal bile Acid Transporter inhibitor, for the treatment of chronic idiopathic constipation. Expert Opin Pharmacother. 2018;19(12):1381–8. https://doi.org/10.1080/14656566.2018.1508450. PubMed PMID: 30129377.CrossRefPubMed

16.

Lasa JS, Altamirano MJ, Bracho LF, Paz S, Zubiaurre I, 13., EFFICACY AND SAFETY OF INTESTINAL SECRETAGOGUES FOR CHRONIC CONSTIPATION: A SYSTEMATIC REVIEW AND META-ANALYSIS. Arq Gastroenterol. 2018;55(Suppl 1):2–12. https://doi.org/10.1590/s0004-2803.201800000-41. PubMed PMID: 30088533. Suppl 1.

17.

Luthra P, Camilleri M, Burr NE, Quigley EMM, Black CJ, Ford AC. 14. Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(11):831 – 44. Epub 20190829. https://doi.org/10.1016/s2468-1253(19)30246-8. PubMed PMID: 31474542.

18.

Nakajima A, Shoji A, Kokubo K, Igarashi A. 15. A Systematic Review and Network Meta-Analysis on the Efficacy of Medications in the Treatment of Chronic Idiopathic Constipation in Japan. Gastroenterol Res Pract. 2021;2021:5534687. Epub 20211130. https://doi.org/10.1155/2021/5534687. PubMed PMID: 34887919; PubMed Central PMCID: PMCPMC8651382.

19.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. 16. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. https://doi.org/10.1186/s13643-021-01626-4. PubMed PMID: 33781348; PubMed Central PMCID: PMCPMC8008539.CrossRefPubMedPubMedCentral

20.

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. 17. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898. Epub 20190828. https://doi.org/10.1136/bmj.l4898. PubMed PMID: 31462531.

21.

Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman ND et al. 18. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol. 2014;6:359 – 68. Epub 20141010. https://doi.org/10.2147/clep.S66677. PubMed PMID: 25336990; PubMed Central PMCID: PMCPMC4199858.

22.

Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305(6846):160–4. https://doi.org/10.1136/bmj.305.6846.160. PubMed PMID: 1285753; PubMed Central PMCID: PMCPMC1883187.CrossRefPubMedPubMedCentral

23.

Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol. 2005;40(5):540–51. 10.1080/00365520510012208. PubMed PMID: 16036506.CrossRefPubMed

24.

Nomura H, Agatsuma T, Mimura T. Validity and reliability of the Japanese version of the Patient Assessment of Constipation Quality of Life questionnaire. J Gastroenterol. 2014;49(4):667 – 73. Epub 20130509. https://doi.org/10.1007/s00535-013-0825-y. PubMed PMID: 23657607.

25.

Kanazawa M, Drossman DA, Shinozaki M, Sagami Y, Endo Y, Palsson OS, et al. 19. Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J). Biopsychosoc Med. 2007;1:6. https://doi.org/10.1186/1751-0759-1-6. PubMed PMID: 17371576; PubMed Central PMCID: PMCPMC1832201.CrossRefPubMedPubMedCentral

26.

Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. 20. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:Ed000142. https://doi.org/10.1002/14651858.Ed000142. PubMed PMID: 31643080.CrossRefPubMed

27.

Gopal S, Berwaerts J, Nuamah I, Akhras K, Coppola D, Daly E, et al. 24. Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. Neuropsychiatr Dis Treat. 2011;7:93–101. https://doi.org/10.2147/ndt.S17177. PubMed PMID: 21552311; PubMed Central PMCID: PMCPMC3083982.CrossRefPubMedPubMedCentral

28.

Andrade C. 25. The numbers needed to treat and harm (NNT, NNH) statistics: what they tell us and what they do not. J Clin Psychiatry. 2015;76(3):e330-3. https://doi.org/10.4088/JCP.15f09870. PubMed PMID: 25830454.

29.

Mendes D, Alves C, Batel-Marques F. 26. Number needed to treat (NNT) in clinical literature: an appraisal. BMC Med. 2017;15(1):112. Epub 20170601. https://doi.org/10.1186/s12916-017-0875-8. PubMed PMID: 28571585; PubMed Central PMCID: PMCPMC5455127.

30.

Mathie RT, Ramparsad N, Legg LA, Clausen J, Moss S, Davidson JR et al. 27. Randomised, double-blind, placebo-controlled trials of non-individualised homeopathic treatment: systematic review and meta-analysis. Syst Rev. 2017;6(1):63. Epub 20170324. https://doi.org/10.1186/s13643-017-0445-3. PubMed PMID: 28340607; PubMed Central PMCID: PMCPMC5366148.

31.

Yang T, Wang K, Cao Y, Wen J, Wei S, Li H, et al. 28. Different doses of prucalopride in treating chronic idiopathic constipation: a meta-analysis and bayesian analysis. BMJ Open. 2021;11(2):e039461. https://doi.org/10.1136/bmjopen-2020-039461. PubMed PMID: 33589446; PubMed Central PMCID: PMCPMC7887359.CrossRefPubMedPubMedCentral

32.

Yang J, Wang HP, Zhou L, Xu CF. 29. Effect of dietary fiber on constipation: a meta analysis. World J Gastroenterol. 2012;18(48):7378–83. https://doi.org/10.3748/wjg.v18.i48.7378. PubMed PMID: 23326148; PubMed Central PMCID: PMCPMC3544045.CrossRefPubMedPubMedCentral

33.

Johanson JF, Morton D, Geenen J, Ueno R. 30. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103(1):170-7. Epub 20071004. https://doi.org/10.1111/j.1572-0241.2007.01524.x. PubMed PMID: 17916109.

34.

Fukudo S, Hongo M, Kaneko H, Takano M, Ueno R. 22. Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation. Clin Gastroenterol Hepatol. 2015;13(2):294–301e5. https://doi.org/10.1016/j.cgh.2014.08.026. PubMed PMID: 25158925.CrossRefPubMed

35.

Fukudo S, Hongo M, Kaneko H, Ueno R. 31. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil. 2011;23(6):544-e205. Epub 20110209. https://doi.org/10.1111/j.1365-2982.2011.01668.x. PubMed PMID: 21303430.

36.

Eguchi T, Yoshizaki T, Takagi M, Ikeoka S, Hashimura H, Okamoto N, et al. 32. Risk factors for adverse events in patients with chronic constipation following Lubiprostone Administration. Dig Dis. 2021;39(1):10–5. Epub 20200525. doi: 10.1159/000508864. PubMed PMID: 32450563.CrossRefPubMed

37.

Barish CF, Drossman D, Johanson JF, Ueno R. 33. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci. 2010;55(4):1090-7. Epub 20091211. https://doi.org/10.1007/s10620-009-1068-x. PubMed PMID: 20012484.

38.

Fukudo S, Miwa H, Nakajima A, Kinoshita Y, Kosako M, Hayashi K, et al. 34. High-dose linaclotide is effective and safe in patients with chronic constipation: a phase III randomized, double-blind, placebo-controlled study with a long-term open-label extension study in Japan. Neurogastroenterol Motil. 2019;31(1):e13487. https://doi.org/10.1111/nmo.13487. PubMed PMID: 30353619; PubMed Central PMCID: PMCPMC7379198.CrossRefPubMed

39.

Fukudo S, Miwa H, Nakajima A, Kinoshita Y, Kosako M, Nakagawa A et al. 35. Dose-finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double-blind, and placebo-controlled study. Neurogastroenterol Motil. 2018;30(12):e13442. Epub 20180807. https://doi.org/10.1111/nmo.13442. PubMed PMID: 30084233.

40.

Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, et al. 36. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365(6):527–36. doi: 10.1056/NEJMoa1010863. PubMed PMID: 21830967.CrossRefPubMed

41.

Lacy BE, Schey R, Shiff SJ, Lavins BJ, Fox SM, Jia XD, et al. 37. Linaclotide in chronic idiopathic constipation patients with moderate to severe abdominal bloating: a Randomized, Controlled Trial. PLoS ONE. 2015;10(7):e0134349. https://doi.org/10.1371/journal.pone.0134349. PubMed PMID: 26222318; PubMed Central PMCID: PMCPMC4519259.CrossRefPubMedPubMedCentral

42.

Schoenfeld P, Lacy BE, Chey WD, Lembo AJ, Kurtz CB, Reasner DS, et al. 38. Low-Dose Linaclotide (72 µg) for chronic idiopathic constipation: a 12-Week, Randomized, Double-Blind, placebo-controlled trial. Am J Gastroenterol. 2018;113(1):105–14. https://doi.org/10.1038/ajg.2017.230. PubMed PMID: 29091082; PubMed Central PMCID: PMCPMC5770595.CrossRefPubMed

43.

Tomie A, Yoshida N, Kugai M, Hirose R, Dohi O, Inoue K et al. 39. The Efficacy and Safety of Elobixibat for the Elderly with Chronic Constipation: A Multicenter Retrospective Cohort Study. Gastroenterol Res Pract. 2020;2020:9656040. Epub 20200428. https://doi.org/10.1155/2020/9656040. PubMed PMID: 32411210; PubMed Central PMCID: PMCPMC7204088.

44.

Nakajima A, Seki M, Taniguchi S. 40. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial. J Gastroenterol. 2018;53(4):525 – 34. Epub 20170824. doi: 10.1007/s00535-017-1383-5. PubMed PMID: 28840422; PubMed Central PMCID: PMCPMC5866829.

45.

Nakajima A, Seki M, Taniguchi S, Ohta A, Gillberg PG, Mattsson JP, et al. 21. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3(8):537–47. https://doi.org/10.1016/s2468-1253(18)30123-7. PubMed PMID: 29805116.CrossRefPubMed

46.

Chey WD, Camilleri M, Chang L, Rikner L, Graffner H. 41. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol. 2011;106(10):1803–12. https://doi.org/10.1038/ajg.2011.162. PubMed PMID: 21606974; PubMed Central PMCID: PMCPMC3188811.CrossRefPubMedPubMedCentral

47.

Lembo AJ, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA et al. 45. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010;138(3):886 – 95.e1. Epub 20100104. https://doi.org/10.1053/j.gastro.2009.12.050. PubMed PMID: 20045700.

48.

Passos M, Takemoto MLS, Corradino GC, Guedes LS. 46. Systematic review with meta-analysis: lubiprostone efficacy on the treatment of patients with constipation. Arq Gastroenterol. 2020;57(4):498–506. https://doi.org/10.1590/s0004-2803.202000000-83. PubMed PMID: 33331483.CrossRefPubMed

49.

Videlock EJ, Cheng V, Cremonini F. 49. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(9):1084-92.e3; quiz e68. Epub 20130502. https://doi.org/10.1016/j.cgh.2013.04.032. PubMed PMID: 23644388.

50.

Nelson AD, Camilleri M, Chirapongsathorn S, Vijayvargiya P, Valentin N, Shin A et al. 50. Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis. Gut. 2017;66(9):1611-22. Epub 20160610. https://doi.org/10.1136/gutjnl-2016-311835. PubMed PMID: 27287486.

Title: Comparative profiles of lubiprostone, linaclotide, and elobixibat for chronic constipation: a systematic literature review with meta-analysis and number needed to treat/harm
Authors: Satish S. Rao
Noriaki Manabe
Yusuke Karasawa
Yuko Hasebe
Kazutaka Nozawa
Atsushi Nakajima
Shin Fukudo
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Lubiprostone
Constipation
Constipation
Published in: BMC Gastroenterology / Issue 1/2024
Electronic ISSN: 1471-230X
DOI: https://doi.org/10.1186/s12876-023-03104-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Design

Methods

Primary and secondary outcome measures

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Identification of a vascular invasion-related signature based on lncRNA pairs for predicting prognosis in hepatocellular carcinoma

Inside stent placement is suitable for preoperative biliary drainage in patients with perihilar cholangiocarcinoma

Evaluating the efficacy of different volume resuscitation strategies in acute pancreatitis patients: a systematic review and meta-analysis

The burden and predictors of 30-day unplanned readmission in patients with acute liver failure: a national representative database study

Correction: PTEN-induced kinase 1 gene single-nucleotide variants as biomarkers in adjuvant chemotherapy for colorectal cancer: a retrospective study

A comprehensive study on non-cancer-related mortality risk factors in elderly gastric cancer patients post-curative surgery

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage